Prophase Labs Inc Stock Price, News & Analysis

ProPhase Labs, Inc. (NASDAQ: PRPH) will hold a conference call on November 10, 2022, at 11:00 a.m. Eastern time to discuss its third quarter results for the period ended September 30, 2022. A press release with detailed results will be issued prior to the call. The call will be hosted by CEO Ted Karkus and feature a Q&A session. Participants can register online or use dial-in numbers for access. The call will also be broadcast live and accessible for replay.

ProPhase Labs, Inc. (NASDAQ: PRPH) has announced a collaboration with G42 Healthcare to enhance genomic sequencing capabilities. This partnership aims to create an advanced genomic sequencing facility in the U.S. and explore opportunities in genomic data sharing and artificial intelligence. The initiative focuses on the development of personalized medical treatments, targeting high-growth markets globally. ProPhase plans to expand its New York headquarters and intends to leverage its CLIA lab services for whole genome sequencing and diagnostics, aiming for operational efficiencies and cost savings.

ProPhase Labs, Inc. (NASDAQ: PRPH) will participate in The ThinkEquity Conference on October 26, 2022, at the Mandarin Oriental Hotel in New York. CEO Ted Karkus is scheduled to present at 11:30 AM ET. The event will include opportunities for one-on-one investor meetings and will also be live-streamed. ProPhase Labs focuses on diagnostics, genomics, and biotech, leveraging CLIA lab services for whole genome sequencing and COVID-19 testing. Visit www.ProPhaseLabs.com for more information.

ProPhase Labs, Inc. (NASDAQ: PRPH) announced the addition of Dr. Russ B. Altman to the Advisory Board of its subsidiary, Nebula Genomics. Dr. Altman is a distinguished professor at Stanford University with expertise in bioengineering and genomics. His appointment is expected to enhance Nebula's strategic direction and product development in direct-to-consumer whole genome sequencing. ProPhase also plans to significantly expand its Garden City headquarters, building a new genomics lab equipped for advanced sequencing and genetic testing.

ProPhase Labs, a diversified diagnostics and biotech company, will present at the H.C. Wainwright 24th Annual Global Investment Conference on September 12, 2022, at 2:30 PM ET. CEO Ted Karkus will overview the company's offerings, including genomic services and COVID-19 testing. The hybrid conference runs from September 12-14, 2022, at the Lotte New York Palace Hotel. Interested institutional investors can register here.

ProPhase Labs (NASDAQ: PRPH) reported record Q2 2022 net revenues of $29.1 million, a 218% increase year-over-year, alongside a net income of $7.4 million, up 633% from the previous year. Adjusted EBITDA reached $12.4 million. The company performed 188,000 diagnostic tests in the quarter, significantly up from 56,000 in Q2 2021. Cash and equivalents totaled $27.5 million, with working capital at $53.5 million. Future expansions include a new subsidiary for drug development and a $6 million stock repurchase program.

ProPhase Labs (NASDAQ: PRPH) will hold a conference call on August 11, 2022 at 11:00 a.m. ET to discuss its second-quarter results for the period ending June 30, 2022. CEO Ted Karkus will lead the call, which includes a Q&A session. Interested participants can register for the call via the provided link or dial in using the toll-free number 1-866-777-2509. The call will also be accessible for replay shortly after it concludes. ProPhase Labs focuses on diagnostics, genomics, and biotech services, including COVID-19 testing and genome sequencing.

ProPhase Labs (NASDAQ: PRPH) announced a $6 million stock repurchase program, effective three business days post its quarterly earnings release on August 12, 2022. The program allows for repurchases over six months via open market or negotiated transactions. CEO Ted Karkus emphasized this move reflects confidence in the company's multi-faceted strategy and aims to enhance shareholder value. ProPhase BioPharma plans to begin animal studies for its LB-1 cancer therapy with an estimated $5 million R&D budget, expecting to generate net income exceeding this amount in Q2 2022.

ProPhase Labs, Inc. (NASDAQ: PRPH) announced the grant of an inducement stock option to Dennis Grishin, its new Chief Scientific Officer, allowing him to purchase up to 250,000 shares at an exercise price of $13.00 per share. This option vests 50% immediately and the remainder in annual installments over two years, with a total exercisable period of 7 years. This grant complies with Nasdaq Rule 5635(c)(4) and was not part of the stockholder-approved equity plan. ProPhase continues to advance genomics testing and diagnostics services.